Max Nisen, Columnist

Valeant Walks a Thin Green Line

Its cash pile is dwindling, while its debt is not.

November 1, 2016 at 1:37 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

On Halloween 2016, Valeant Pharmaceuticals International Inc. saw some ghosts.

The specialty pharmaceutical firm's shares fell 12 percent on Monday, after Bloomberg News reported ex-CEO Michael Pearson and ex-CFO Howard Schiller are the subjects of a criminal probe over potential accounting fraud, related to Valeant's now-dead (or undead?) relationship with the specialty pharmacy Philidor.